Anticoagulation in hospitalized patients with COVID-19.

ABSTRACT: Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.

SUBMITTER: Baumann Kreuziger L 

PROVIDER: S-EPMC9361053 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature